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Mutations in hemojuvelin (HJV) are the most common cause of the juvenile-onset form of
the iron overload disorder hereditary hemochromatosis. The discovery that HJV functions
as a co-receptor for the bone morphogenetic protein (BMP) family of signaling molecules
helped to identify this signaling pathway as a central regulator of the key iron hormone
hepcidin in the control of systemic iron homeostasis. This review highlights recent work
uncovering the mechanism of action of HJV and the BMP-SMAD signaling pathway in
regulating hepcidin expression in the liver, as well as additional studies investigating
possible extra-hepatic functions of HJV. This review also explores the interaction between
HJV, the BMP-SMAD signaling pathway and other regulators of hepcidin expression in
systemic iron balance.
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JUVENILE HEMOCHROMATOSIS IS CAUSED BY MUTATIONS
IN THE GENES ENCODING HEPCIDIN OR HEMOJUVELIN
Juvenile Hemochromatosis (JH) is an autosomal recessive dis-
order caused by a failure to prevent excess iron entry into
the bloodstream, and characterized by progressive tissue iron
overload (Pietrangelo, 2010). Although iron’s redox properties
are critical for its role in many fundamental biological pro-
cesses from cellular respiration to oxygen transport, iron excess
can lead to toxic free radical generation. If left untreated, JH
patients develop multiorgan dysfunction as a consequence of
iron overload, including cirrhosis, cardiomyopathy, diabetes mel-
litus, and hypogonadotrophic hypogonadism, before the age of 30
(Pietrangelo, 2010).
The identification of hepcidin as a master regulator of sys-
temic iron balance was a major advance in understanding
the pathophysiology of JH (Ganz, 2013). A defensin-like pep-
tide produced predominantly by hepatocytes, hepcidin controls
iron entry into the bloodstream from dietary sources, recycled
red blood cells, and body storage sites by inducing degrada-
tion of the iron exporter ferroportin (Ganz, 2013). Hepcidin
expression is stimulated by iron and inflammation to limit
iron availability, while hepcidin is inhibited by iron deficiency,
anemia, and hypoxia to increase iron availability for erythro-
poiesis (Babitt and Lin, 2010; Ganz, 2013). Hepcidin defi-
ciency is the common pathogenic mechanism underlying both
adult and juvenile-onset hemochromatosis and contributes to
the pathogenesis of iron loading anemias such as thalassemia,
while its overproduction causes anemia of inflammation and
iron refractory iron deficiency anemia (IRIDA) (Ganz, 2013).
JH is caused by mutations in the gene encoding hepcidin itself
(HAMP) or, more commonly, hemojuvelin (HJV, also known
as HFE2 or RGMC) (Roetto et al., 2003; Papanikolaou et al.,
2004).
HJV encodes a glycophosphatidylinositol (GPI)-linked mem-
brane protein that is a member of the repulsive guidance
molecule (RGM) family (Monnier et al., 2002; Samad et al.,
2004). Currently, there are 43 identified HJV mutations that
cause JH, with G320V being the most frequent (Table 1). HJV
is expressed in the liver, and JH patients with HJV mutations
andHjv knockout mice exhibit significantly reduced hepatic hep-
cidin expression, thereby implicating HJV in the regulation of
hepcidin synthesis (Papanikolaou et al., 2004; Huang et al., 2005;
Niederkofler et al., 2005).
BMP-SMAD SIGNALING VIA HJV IS A CENTRAL REGULATOR
OF HEPCIDIN
A breakthrough in understanding the mechanism of action of
HJV in hepcidin regulation came when HJV was discovered to
function as a co-receptor for the bone morphogenetic protein
(BMP) signaling pathway (Babitt et al., 2006), analogous to its
RGM family homologs (Babitt et al., 2005; Samad et al., 2005).
Importantly, this BMP signaling function of HJV was demon-
strated to be crucial for its role in regulating hepcidin expression
(Babitt et al., 2006) (Figure 1).
BMPs belong to the Transforming Growth Factor-beta (TGF-
β) superfamily of ligands (Shi and Massagué, 2003). In the
canonical signaling pathway, BMP ligands bind to type I and type
II serine threonine kinase receptors to induce phosphorylation
of cytoplasmic SMAD1, SMAD5, and SMAD8 proteins. These
SMAD proteins form a complex with SMAD4 and translocate to
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Table 1 | Mutations of the HJV gene linked to JH.
Residue mutation Exon Type of Nucleotide Family origin References
mutation change
Q6H 2 Missense 18G > C Asian Huang et al., 2004
L27fsX51 2 Frame shift 81delG English/Irish Wallace et al., 2007
R54X 3 Nonsense 160A > T African American Murugan et al., 2008
G66X 3 Nonsense 196G > T Romanian Jánosi et al., 2005
V74fsX113 3 Frame shift 220delG English Lanzara et al., 2004
C80R 3 Missense 238T > C Caucasian Lee et al., 2004
S85P 3 Missense 253T > C Italian Lanzara et al., 2004
G99R 3 Missense 295G > A Albanian Lanzara et al., 2004
G99V 3 Missense 296G > T Multiple Papanikolaou et al., 2004; Silvestri et al., 2007
L101P 3 Missense 302T > C Albanian Lanzara et al., 2004; Lee et al., 2004
G116X 3 Nonsense Santos et al., 2012
C119F 3 Missense G356 > T German Gehrke et al., 2005; Silvestri et al., 2007
R131fsX245 3 Frame shift 391-403del Italian Lanzara et al., 2004
D149fsX245 3 Frame shift 445delG Italian Lanzara et al., 2004
L165X 3 Nonsense 494T > A van Dijk et al., 2007
A168D 3 Missense 503C > A Australian /English Lanzara et al., 2004
F170S 3 Missense 509T > C Italian De Gobbi et al., 2002; Lanzara et al., 2004; Silvestri
et al., 2007
D172E 3 Missense 516C > G Italian Lanzara et al., 2004
R176C 3 Missense 526C > T European Aguilar-Martinez et al., 2007; Ka et al., 2007
W191C 3 Missense 573G > T Italian De Gobbi et al., 2002; Lanzara et al., 2004; Silvestri
et al., 2007
N196K 3 Missense 588T > G Santos et al., 2012
S205R 3 Missense 615C > G Italian Lanzara et al., 2004
I222N 4 Missense 665T > A Canadian Papanikolaou et al., 2004
K234X 4 Nonsense 700-703AAG del European Santos et al., 2012
D249H 4 Missense 745G > C Asian Santos et al., 2012
G250V 4 Missense 749G > T Italian Lanzara et al., 2004
N269fsX311 4 Frame shift 806 > 807insA English Lanzara et al., 2004
I281T 4 Missense 842T > C Multiple Huang et al., 2004; Papanikolaou et al., 2004
C282Y 4 Missense Caucasian Le Gac et al., 2004
R288W 4 Missense 863C > T French Lanzara et al., 2004
R288Y 4 Missense 862C > T Wallace et al., 2007
E302K 4 Missense 904G > A Brazilian Santos et al., 2011
A310G 4 Missense 929C > G Brazilian de Lima Santos et al., 2010; Santos et al., 2011
Q312X 4 Nonsense 934C > T Asian Nagayoshi et al., 2008
G319fsX341 4 Frame shift 954-955insG Italian Lanzara et al., 2004
G320V 4 Missense 959G > T Multiple Lanzara et al., 2004; Papanikolaou et al., 2004; Gehrke
et al., 2005; Silvestri et al., 2007; Santos et al., 2011
C321W 4 Missense 963C > G European Wallace et al., 2007
C321X 4 Nonsense 962G > A, 963C > A Asian Huang et al., 2004; Santos et al., 2012
R326X 4 Nonsense 976C > T Asian Huang et al., 2004; Papanikolaou et al., 2004
S328fsX337 4 Frame shift 980-983 delTCTC Slovakian Gehrke et al., 2005
R335Q 4 Missense 1004G > A Wallace et al., 2007
C361fsX366 4 Frame shift 1080delC European Papanikolaou et al., 2004
N372D 4 Missense 1114A > G Wallace et al., 2007
R385X 4 Nonsense 1153C > T Italian Lanzara et al., 2004; Santos et al., 2012
the nucleus to regulate gene transcription. This signaling path-
way is further regulated at multiple levels in order to generate
a precise signal in a specific cellular context (Shi and Massagué,
2003).
HJV and other RGM family members function as BMP co-
receptors that bind selectively to BMP ligands and receptors
to enhance SMAD phosphorylation in response to BMP sig-
nals (Babitt et al., 2005, 2006; Samad et al., 2005). All RGMs
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FIGURE 1 | Schematic diagram showing the central role of the
BMP6-HJV-SMAD signaling pathway in hepcidin regulation and the
proposed interaction with other hepcidin regulators. BMP6 binds to
the BMP type I and type II receptors (BMPR) and the co-receptor HJV to
increase phosphorylation of SMAD1, SMAD5, and SMAD8 proteins
(SMAD1/5/8), which translocate to the nucleus to increase hepcidin
transcription. Numerous other hepcidin regulators have been identified,
many of which are proposed to intersect with the central
BMP6/HJV/SMAD pathway at various levels as shown. Proposed
iron-mediated hepcidin regulators are shown in yellow, inflammatory
mediators in blue, iron deficiency mediators in purple, and anemia
mediators in red. Abbreviations: TFR2, transferrin receptor 2; IL6,
interleukin 6, sHJV, soluble hemojuvelin, TWSG1, twisted gastrulation 1,
GDF15, growth and differentiation factor 15, TMPRSS6, transmembrane
serine proteinase 6, EGF, epidermal growth factor, HGF, hepatocyte
growth factor, mTOR, mammalian target of rapamycin.
share the ability to bind to the BMP2/BMP4 subfamily and
enhance BMP2/BMP4 signaling (Babitt et al., 2005, 2006; Samad
et al., 2005; Wu et al., 2012). Moreover, all RGMs utilize BMP
type I receptors ALK2, ALK3, and ALK6, and allow prefer-
ential signaling through the BMP type II receptor ACTRIIA
(Xia et al., 2007, 2008, 2010). However, HJV is unique from
other RGMs in that it exhibits preferential ability to bind to
the BMP5/BMP6/BMP7 subfamily compared with RGMA and
RGMB (Wu et al., 2012).
The BMP-HJV-SMAD signaling pathway activates hepcidin
transcription directly through specific BMP-responsive elements
(BMP-REs) on the hepcidin promoter (Casanovas et al., 2009;
Truksa et al., 2009a). A mutation in the proximal BMP-RE
was associated with a more severe iron overload phenotype in
a patient with classical HFE hemochromatosis, demonstrating
its importance in hepcidin regulation in humans (Island et al.,
2009). Inmice, liver-specific disruption of Smad4, the BMP recep-
tors type I Alk2 or Alk3, or the ligand Bmp6 result in hepcidin
deficiency and iron overload, supporting the important role of
these specific BMP-SMAD pathway components, in conjunction
with HJV, in hepcidin regulation in vivo (Wang et al., 2005;
Andriopoulos et al., 2009; Meynard et al., 2009; Steinbicker et al.,
2011a).
SOLUBLE HJV
In addition to the GPI-anchoredmembrane form ofHJV, endoge-
nous soluble HJV (sHJV) protein is detectable in human and
rodent serum. (Lin et al., 2005; Zhang et al., 2007; Chen et al.,
2013). Multiple mechanisms have been proposed for endogenous
sHJV generation, including cleavage by the pro-protein con-
vertase furin and the type II transmembrane serine protease
TMPRSS6 (Kuninger et al., 2008; Lin et al., 2008; Silvestri et al.,
2008a,b). Whereas membrane HJV is a co-receptor for the BMP
signaling complex (Babitt et al., 2006), sHJV can antagonize BMP
signaling, presumably by binding and sequestering BMP ligands
from interacting with cell-surface BMP type I and type II recep-
tors (Babitt et al., 2007) (Figure 1). Indeed, the relative binding
affinity of HJV for various BMP ligands roughly correlated with
the ability of sHJV to inhibit their biological activity (Babitt et al.,
2007; Wu et al., 2012).
Although exogenous sHJV inhibits BMP-SMAD signaling, the
source, amount, and physiologic role(s) of endogenously pro-
duced sHJV in vivo are not well-understood. There is some
evidence suggesting that endogenous sHJV is increased by iron
deficiency and reduced by iron loading (Lin et al., 2005; Zhang
et al., 2007; Silvestri et al., 2008a; Brasse-Lagnel et al., 2010;
Chen et al., 2013). Interestingly, the furin cleaved form of sHJV
appears to be more potent to inhibit BMP signaling and hep-
cidin compared with the TMPRSS6-cleaved form (Maxson et al.,
2010). Whether HJV cleavage mainly represents a mechanism to
remove the activating effects of liver membrane HJV, or whether
endogenous sHJV has a direct BMP-SMAD inhibiting effect
remains uncertain.
EXTRA-HEPATIC FUNCTIONS OF HJV
In addition to the liver, HJV mRNA is also highly expressed
in skeletal muscle and heart (Niederkofler et al., 2004;
Papanikolaou et al., 2004), and has been detected in other
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tissues (Rodriguez Martinez et al., 2004, Rodriguez et al., 2007;
Gnana-Prakasam et al., 2009; Luciani et al., 2011). Tissue specific
differences in HJV mRNA regulation and HJV protein glyco-
sylation patterns have also been described (Niederkofler et al.,
2005; Fujikura et al., 2011). It was previously hypothesized that
skeletal muscle and/or heart could serve as a source of sHJV
to suppress hepcidin synthesis in response to iron deficiency or
hypoxia (Lin et al., 2005; Zhang et al., 2005). However, mice
with a specific knockout of Hjv in skeletal ± cardiac muscle
do not have altered hepcidin expression or systemic iron bal-
ance, at least under basal conditions or with dietary iron changes
(Chen et al., 2011; Gkouvatsos et al., 2011). Whether strenuous
exercise or hypoxia may uncover a role for muscle hemojuvelin
remains uncertain. In contrast, hepatocyte specific Hjv knock-
out mice exhibit an iron overload phenotype similar to global
Hjv knockout mice (Chen et al., 2011; Gkouvatsos et al., 2011).
Thus, hepatic expression of HJV appears to have the most impor-
tant physiologic role in systemic iron homeostasis regulation
in vivo.
IRON STIMULATES BMP-SMAD SIGNALING TO REGULATE
HEPCIDIN
Iron regulates the activity of the BMP6-SMAD pathway to
modulate hepcidin expression. Both circulating and liver iron
appear to stimulate this pathway through different mechanisms
(Ramos et al., 2011; Corradini et al., 2011a). In mice, liver
iron content is positively correlated with liver Bmp6 mRNA lev-
els and overall activity of the Smad signaling pathway (Kautz
et al., 2008; Corradini et al., 2011a). Moreover, hepcidin induc-
tion by iron is inhibited by a neutralizing BMP6 antibody
(Corradini et al., 2011a). These data suggest that liver iron mod-
ulates BMP6-SMAD signaling and hepcidin expression at least
in part by regulating expression of BMP6 mRNA (Figure 1).
It appears that liver iron regulates BMP6 expression mainly in
nonparenchymal cells (Enns et al., 2013), and that iron load-
ing in specific liver cell types may important for this regula-
tion (Daba et al., 2013). However, the mechanism by which
hepatic iron levels regulate BMP6 remains unknown. Notably,
hepcidin is still increased to a lesser extent by chronic iron
loading in Bmp6 and Hjv knockout mice, suggesting that these
pathways do not completely account for hepcidin regulation by
chronic iron loading (Ramos et al., 2011; Gkouvatsos et al.,
2014).
Increases in circulating iron stimulate SMAD1/5/8 phospho-
rylation and hepcidin expression without affecting Bmp6 mRNA
levels (Corradini et al., 2011a). How circulating iron activates
SMAD1/5/8 phosphorylation is unknown, but may involve an
interaction with other proteins that are mutated in adult-onset
hereditary hemochromatosis (see section HFE and TFR2). HJV
liver membrane protein expression itself does not appear to be
regulated by iron (Krijt et al., 2012).
Iron administration and BMP6-SMAD signaling also up-
regulate inhibitory SMAD7 and SMAD6, and TMPRSS6 (see
section TMPRSS6), that can act as feedback inhibitors of BMP-
SMAD signaling and hepcidin expression (Kautz et al., 2008;
Mleczko-Sanecka et al., 2010; Meynard et al., 2011; Corradini
et al., 2011a; Vujic´ Spasic´ et al., 2013). It has been hypothesized
that these pathways may help prevent excessive hepcidin increases
by iron to provide tight homeostatic control (Meynard et al.,
2011; Corradini et al., 2011a).
INTERACTION OF HJV AND THE BMP-SMAD SIGNALING
PATHWAYWITH OTHER HEPCIDIN REGULATORS
HFE AND TFR2
Adult-onset hereditary hemochromatosis is a less severe iron-
overload disorder that manifests later in life compared with JH,
and is associated with mutations in HFE or TFR2 (encoding
transferrin receptor 2) (Pietrangelo, 2010). Liver expression of
HFE and TFR2 are clearly important for iron homeostasis reg-
ulation because mice with a hepatocyte-specific knockout of
either gene have a similar iron-overload phenotype compared
with global Hfe or Tfr2 knockout mice (Wallace et al., 2007;
Vujic´ Spasic´ et al., 2008). Moreover, liver transplantation corrects
much of the HFE hemochromatosis phenotype (Garuti et al.,
2010; Bardou-Jacquet et al., 2014). Liver hepcidin expression is
inappropriately low in mice and humans with HFE or TFR2
mutations, suggesting that both HFE and TFR2 positively regu-
late liver hepcidin expression (Ahmad et al., 2002; Fleming et al.,
2002; Bridle et al., 2003; Muckenthaler et al., 2003; Kawabata
et al., 2005; Nemeth et al., 2005; Piperno et al., 2007). HFE
and TFR2 are also postulated to function in iron sensing by
the liver. The current working model is that when iron-bound
transferrin increases in circulation, it binds to transferrin recep-
tor 1 (TFR1) and displaces HFE, which then signals by some
mechanism to stimulate hepcidin expression, possibly through
an interaction with TFR2 (Schmidt et al., 2008; Gao et al.,
2009).
It has been proposed that HFE and TFR2 may form a
“supercomplex” with HJV to stimulate hepcidin expression via
the BMP-SMAD pathway. Studies supporting this model have
demonstrated that liver BMP-SMAD signaling is impaired in
mice and humans with HFE and/or TFR2 mutations, suggest-
ing an interaction at some level between HFE, TFR2 and the
BMP-SMAD pathway (Corradini et al., 2009, 2011b; Kautz et al.,
2009; Wallace et al., 2009; Bolondi et al., 2010; Ryan et al., 2010).
Recently, it was published in an overexpression tissue culture sys-
tem using tagged proteins that HFE and TFR2 can form a complex
with HJV (D’Alessio et al., 2012). However, it is not been shown
whether these proteins endogenously interact in vivo. Moreover,
the more severe iron overload phenotype of HJV mutations and
combined HFE/TFR2 mutations compared with either HFE or
TFR2 mutations alone suggest that the function of these proteins
is not entirely overlapping (Pietrangelo et al., 2005; Wallace et al.,
2009). Thus, while it appears that HFE and TFR2 interact at some
level with the BMP-HJV-SMAD pathway to regulate liver hep-
cidin expression (Figure 1), the precise molecular mechanisms of
how HFE and TFR2 contribute to hepcidin regulation remain an
active area of investigation.
THE INFLAMMATORY PATHWAY
In addition to iron, inflammatory stimuli also induce hepcidin
expression (Ganz, 2013). The most well-characterized pathway is
through IL6 activating the Janus kinase JAK2 to phosphorylate
STAT3, which then activates the hepcidin promoter directly via a
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STAT3-binding motif (Wrighting and Andrews, 2006; Pietrangelo
et al., 2007; Verga Falzacappa et al., 2007).
Although inflammation downregulates liver Hjv mRNA
expression (Krijt et al., 2004; Niederkofler et al., 2005; Constante
et al., 2007), liver SMAD1/5/8 signaling is often activated in the
context of inflammation (Theurl et al., 2011) and is essential
for hepcidin regulation by inflammation. Indeed, blocking BMP
signaling with a small molecule BMP type I receptor inhibitor
or a sHJV recombinant protein inhibits IL6-induced hepcidin
expression in cell culture (Babitt et al., 2007; Yu et al., 2008).
Moreover, mice with a hepatocyte-specific knockout of Smad4
exhibit blunted hepcidin response to IL6 treatment (Wang et al.,
2005). Importantly, BMP pathway inhibitors lower hepcidin,
increase iron availability for erythropoiesis, and ameliorate ane-
mia in animal models of anemia of inflammation (Theurl et al.,
2011; Steinbicker et al., 2011b; Sun et al., 2013).
At least two mechanisms are proposed to account for the
crosstalk between the BMP-SMAD and IL6-STAT3 pathways in
hepcidin regulation. First, there may be an interaction at the
level of the hepcidin promoter, where the proximal BMP-RE
and the STAT3 binding site are in close proximity (Figure 1).
In support of this hypothesis, mutation of the proximal BMP-
RE impairs hepcidin promoter activation not only by BMPs,
but also by IL6 (Casanovas et al., 2009). Second, inflamma-
tion induces hepatic expression of another TGF-β superfamily
member, Activin B, which can stimulate hepcidin expression by
activating SMAD1/5/8 signaling in hepatoma-derived cell cul-
tures (Besson-Fournier et al., 2012) (Figure 1). Whether Activin
B contributes to hepcidin regulation by inflammation in vivo
remains to be determined.
TMPRSS6
The serine protease TMPRSS6 has been implicated in hepcidin
inhibition by iron deficiency. Mutations in TMPRSS6 are linked
to IRIDA associated with inappropriately high hepcidin levels
(Du et al., 2008; Finberg et al., 2008; Folgueras et al., 2008).
Moreover, genome-wide association studies have linked com-
mon single nucleotide polymorphisms in TMRPSS6 to iron
status and hemoglobin level, supporting an important role for
TMPRSS6 in regulating systemic iron homeostasis and nor-
mal erythropoiesis (Benyamin et al., 2009; Chambers et al.,
2009; Tanaka et al., 2010). TMPRSS6 is proposed to regulate
hepcidin expression through an interaction with HJV and the
BMP-SMAD pathway in the liver. Specifically, when both pro-
teins are overexpressed in cell culture, TMPRSS6 binds and
cleaves HJV to generate sHJV, thereby inhibiting BMP-SMAD
signaling (Silvestri et al., 2008b) (Figure 1). In mouse mod-
els, the combined deficiency of Hjv or Bmp6 and Tmprss6
causes iron overload, suggesting that there is a genetic inter-
action between TMPRSS6 and the BMP6-HJV-SMAD pathway
(Truksa et al., 2009b; Finberg et al., 2010; Lenoir et al., 2011).
Interestingly, liver membrane expression of Hjv is decreased
(Krijt et al., 2011), and serum sHjv levels are unchanged (Chen
et al., 2013), in Tmprss6 knockout mice compared with wild-
type mice, which seem contrary to the proposed hypothesis that
TMPRSS6 acts to cleave HJV from the liver membrane surface.
Future work is needed to fully understand the mechanism of
action of TMPRSS6 in hepcidin regulation and iron homeostasis
in vivo.
NEOGENIN
In addition to TMPRSS6, the deleted in colorectal cancer (DCC)
family member neogenin is also proposed to function as an HJV
interacting protein that modifies BMP-SMAD signaling and iron
homeostasis (Figure 1). In particular, neogenin binds to HJV,
like other RGM family members (Matsunaga et al., 2004; Zhang
et al., 2005; Conrad et al., 2010). Moreover, neogenin mutant
mice exhibit reduced hepcidin levels and iron overload consis-
tent with a role for neogenin in regulating hepcidin and systemic
iron balance in vivo (Lee et al., 2010). However, the mechanism of
action of neogenin in hepcidin and iron homeostasis regulation
is still not fully understood. In some studies, neogenin increased
HJV cleavage (Enns et al., 2012), while in other studies, neogenin
reduced HJV secretion (Lee et al., 2010). Moreover, neogenin was
variably shown to inhibit (Hagihara et al., 2011), have no effect
(Xia et al., 2008), or stimulate BMP signaling (Lee et al., 2010).
Whether neogenin and HJV interact in a cell autonomous or cell
non-autonomous manner in vivo remains unclear, and how this
interaction occurs may be important for downstream functional
effects.
OTHER PATHWAYS
Hepcidin suppression by erythropoietic drive appears to be medi-
ated by secreted factor(s) released by proliferating red blood cell
precursors in the bone marrow (Pak et al., 2006; Vokurka et al.,
2006). Two proposed erythroid hepcidin regulators are the TGF-
β/BMP superfamily modulators growth and differentiation factor
15 (GDF15) and twisted gastrulation 1 (TWSG1), at least in
the context of ineffective erythropoiesis in iron loading anemias
(Tanno et al., 2007, 2009) (Figure 1). The role of GDF15 and
TWSG1 in hepcidin suppression by erythropoietic drive in other
contexts has been questioned (Ashby et al., 2010; Casanovas et al.,
2013). Recently, erythroferrone has been proposed as a novel ery-
throid regulator (Kautz et al., 2013), but its mechanism of action
is not yet reported.
A number of other hormones, growth factors and signal-
ing pathways have recently been implicated in hepcidin regula-
tion including testosterone, estrogen, hepatocyte growth factor
(HGF), epidermal growth factor (EGF), endoplasmic reticulum
stress, gluconeogenic signals and the Ras/RAF and mTOR sig-
naling pathways (Oliveira et al., 2009; Vecchi et al., 2009, 2014;
Goodnough et al., 2012; Hou et al., 2012; Yang et al., 2012; Guo
et al., 2013; Latour et al., 2014; Mleczko-Sanecka et al., 2014).
Notably, the majority of these pathways appear to regulate hep-
cidin through an intersection with the BMP-SMAD pathway at
some level (Goodnough et al., 2012; Guo et al., 2013; Latour et al.,
2014; Mleczko-Sanecka et al., 2014) (Figure 1).
CONCLUSION
Understanding the genetic basis for JH has yielded impor-
tant insights into the molecular mechanisms of systemic iron
homeostasis. Hepcidin and its receptor ferroportin are key reg-
ulators of body iron balance, and the BMP-SMAD pathway via
the co-receptor HJV is a central regulator of hepcidin production
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(Figure 1). Knowledge of these pathways has already lead to the
development of novel therapeutic strategies that target the molec-
ular mechanisms underlying iron homeostasis disorders, with
several new treatments currently being evaluated in human clin-
ical trials (Fung and Nemeth, 2013). Future work will be needed
to fully understand the mechanisms by which iron levels are
sensed by the liver and integrated with other pathways to reg-
ulate BMP-SMAD signaling, hepcidin expression, and systemic
iron homeostasis.
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